News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech's Worst Winner of 2012


1/4/2013 9:04:10 AM

Shares of Isis Pharmaceuticals rose 40% in 2012 as an advisory panel to the Food and Drug Administration voted that its experimental drug for a rare, genetic form of high cholesterol should be approved. That sounds pretty good, right? Sure — so long as you don’t stop to consider what might have been for Isis or the drug, mipomersen, if it had lived up to its early promise.

Read at Forbes


comments powered by Disqus
Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES